1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Arcoma AB

Arcoma AB

ARCOMA.ST
Arcoma ABSE flagStockholm Stock Exchange
8.22
SEK
-0.18
- -
117.62MMarket Cap

Total Valuation

Arcoma AB carries a market capitalization of 117.62M, placing it among publicly traded companies globally. Its enterprise value stands at 109.40M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap117.62M
Enterprise Value109.40M

Share Statistics

Arcoma AB currently has 14.31M shares outstanding.

Shares Outstanding14.31M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Arcoma AB trades at a trailing price-to-earnings ratio of 18.75. The price-to-sales ratio is 0.92, and the price-to-book ratio stands at 4.71.

PE Ratio18.75
PS Ratio0.92
PB Ratio4.71
P/TBV Ratio2.87
P/FCF Ratio5.37
P/OCF Ratio7.70

Enterprise Valuation

On an enterprise value basis, Arcoma AB trades at an EV/EBITDA multiple of 13.47 and an EV/FCF ratio of 4.71. The EV/Sales ratio of 0.81 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 13.47 provides insight into valuation relative to core operating earnings.

EV / Sales0.81
EV / EBITDA13.47
EV / EBIT13.47
EV / FCF4.71

Financial Position

Arcoma AB maintains a current ratio of 3.01, meaning it holds 3.0x the short-term assets needed to cover near-term liabilities.

Current Ratio3.01
Quick Ratio0.76
Debt / EquityN/A
Debt / EBITDAN/A
Interest Coverage58.02

Financial Efficiency

Arcoma AB posts a return on equity of 25.13 and a return on invested capital of 10.92.

Return on Equity (ROE)25.13
Return on Assets (ROA)8.05
Return on Invested Capital (ROIC)10.92
Return on Capital Employed (ROCE)24.44
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover3.14

Taxes

Over the trailing twelve months, Arcoma AB has paid 1.57M in income taxes, reflecting an effective tax rate of 19.17.

Income Tax1.57M
Effective Tax Rate19.17

Stock Price Statistics

Arcoma AB's stock has declined approximately -16.63286% over the past 52 weeks. The 50-day moving average sits at 8.54, while the 200-day moving average is 8.08.

Beta (5Y)N/A
52-Week Price Change-16.63286%
50-Day Moving Average8.54
200-Day Moving Average8.08
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Arcoma AB generated 134.94M in revenue and converted that into 6.63M in net income, yielding earnings per share of 0.50. EBITDA reached 8.12M, while operating income came in at 8.12M.

Revenue134.94M
Gross Profit54.63M
Operating Income8.12M
Pretax Income8.20M
Net Income6.63M
EBITDA8.12M
EBIT8.12M
Earnings Per Share (EPS)0.50

Balance Sheet

Total book value stands at 26.37M, with working capital of 39.29M providing operational flexibility.

Cash & Cash Equivalents14.81M
Total DebtN/A
Net Debt-14.81M
Equity (Book Value)26.37M
Book Value Per Share2.00
Working Capital39.29M

Cash Flow

Arcoma AB produced 16.13M in operating cash flow over the past twelve months. After subtracting -6.98M in capital expenditures, free cash flow totaled 9.15M - equivalent to 0.69 per share.

Operating Cash Flow16.13M
Capital Expenditures-6.98M
Free Cash Flow9.15M
FCF Per Share0.69

Margins

Arcoma AB operates with a gross margin of 40.48, reflecting its pricing power and cost economics. The operating margin of 6.02 and net profit margin of 4.91 provide insight into operational efficiency.

Gross Margin40.48
Operating Margin6.02
Pretax Margin6.07
Profit Margin4.91
EBITDA Margin6.02

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield1.93
FCF Yield18.61

Stock Splits

Arcoma AB's most recent stock split took place on September 21, 2015 with a 35:36 split ratio.

Last Split Date9/21/2015
Split Ratio35:36

Scores

Arcoma AB posts an Altman Z-Score of 7.13, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score7.13